Table 3.
Renal function and haemodynamic changes following treatment with Infliximab
| Baseline (day –2) | Day 1 | Prior to discharge | |
| MAP (mm Hg) | 71.6 (1.7) | 77 (1.9)*** | 81.1 (3.2)*** |
| SVR (dyn.s/cm5) | 466.1 (81.4) | 552.7 (66.2)* | 786.2 (124)** |
| CO (l/min) | 10.9 (1) | 10 (0.8)* | 8.4 (0.8)* |
| Cardiac index (l/min/m2) | 5.9 (0.5) | 5.3 (0.4)* | 4.7 (0.5)* |
| WHVP (mm Hg) | 38.6 (2.4) | 29.1 (1.4)*** | 27.4 (2.8)*** |
| FHVP (mm Hg) | 15.3 (1.8) | 14.9 (2) | 14.6 (1.7) |
| HVPG (mm Hg) | 23.4 (2.8) | 14.3 (1.9)*** | 12.8 (1.9)*** |
| HBF (ml/min) | 506.2 (42.9) | 591.8 (55.2)* | 646.3 (49.2)*** |
| Central venous pressure (mm Hg) | 12.9 (1.1) | 11.8 (0.7) | 11.7 (0.9) |
| RBF (ml/min) | 424.3 (65.1) | 451.8 (76)* | 506.3 (85.7)** |
| Urinary sodium [>10] (mmol/l) | 10.3 (2.5) | 19 (5.1)* | 23.3 (4.3)** |
| Urine volume [>700] (ml/24 h) | 895.8 (140) | 975.8 (113) | 1122 (109) |
| Creatinine [80–133] (μmol/l) | 90.9 (21.5) | 89 (14.7) | 83.5 (10.6) |
*p<0.05, **p<0.01, ***p<0.001 compared with baseline values.
Numbers of patients included in each part of the haemodynamic assessments (baseline; day 1; prior to discharge): portal haemodynamics (n=9; 8; 5); cardiac haemodynamics (n=7; 7; 5); hepatic/renal blood flow (n=6; 6; 5); and MAP (n=10; 10; 9).
CO, cardiac output; FHVP, free hepatic venous pressure; HBF, hepatic blood flow; HVPG, hepatic venous pressure gradient; MAP, mean arterial pressure; RBF, renal blood flow; SVR, systemic vascular resistance; WHVP, wedged hepatic venous pressure.